Ratio Therapeutics

Next week, Ratio’s CEO, Dr. Jack Hoppin, will participate in a panel discussion at the Targeted Radiopharmaceuticals Target Selection & Drug Design Summit, taking place February 25-27 in Boston, MA. The panel, “Investigating Attributes of a Prime Radiopharmaceutical Target to Match the Properties of a Radioactive Drug,” will take place on Wednesday, February 26 at 9 am ET. To register for the summit, visit: https://lnkd.in/ex3fF_GM #Radiopharmaceuticals #DrugDesign #DrugDiscovery

Ratio’s CSO, Dr. John Babich, was recently featured in this Pharmaceutical-Technology article from Frankie Fattorini that discusses the radiopharmaceutical industry’s continued momentum and its manufacturing needs. 2024 saw record-breaking deal-making, growing investment, and increasing demand for innovative radiopharmaceuticals. While supply chain challenges remain, our industry is rising to the occasion with expanded isotope production and evolving regulatory support. Read the full article: https://lnkd.in/dq7NYSvW #radiopharmaceuticals #biotech #nuclearmedicine

#ICYMI – Recently, Ratio’s CSO, Dr. John Babich participated in a virtual roundtable to discuss FAP-targeted PET imaging and theranostics, hosted by Endpoints News. Watch the replay to learn how FAP-targeted PET introduces a new dimension in tumor evaluation, applicable to a broad range of cancers. https://lnkd.in/ea5kDvwg #radiopharmaceuticals #theranostics

This year’s #WorldCancerDay theme of #UnitedByUnique resonates deeply with all of us here at Ratio, where we recognize that behind every cancer diagnosis is a unique human story. Reminding us of this every day is an art installation in our headquarters which is comprised of a special collection by artists who have used their art to support, process or heal from a cancer journey. You can learn more about these artists here: https://lnkd.in/e3PMaupG At Ratio, we are committed to developing innovative #radiopharmaceutical therapies that target #cancer cells with precision, while minimizing harm to healthy tissue, thereby extending life while maintaining quality.

Ratio’s Executive VP and Head of Preclinical Development Shawn Hillier, Ph.D., and Director of Medicinal Chemistry, Shashikanth Ponnala, Ph.D., recently co-authored a paper in EJNMMI Research titled, “In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation.” The study reveals how different preclinical models affect FAP-tracer behavior and therapy outcomes, underscoring the importance of model selection in advancing cancer theranostics. At Ratio, we are dedicated to advancing the field of radiopharmaceuticals, not just through our own innovations but by contributing to critical preclinical research. By improving the understanding of FAP-targeted therapies, we aim to support the development of more effective cancer treatments and bring them to patients faster. Read the full article: https://lnkd.in/etpA_3UB

In this episode of Citeline Commercial’s In Vivo podcast, Jack Hoppin, CEO of Ratio Therapeutics, joins a panel of biotech executives for a dynamic discussion on dealmaking in 2024. Jack highlights the challenges and opportunities facing companies developing radiopharmaceuticals and cancer therapeutics. The panel also shares their perspectives on dealmaking in 2025, offering insights and hopes for the year ahead. Listen here: https://lnkd.in/gKSYuvDb #CancerTreatment #Radiopharmaceuticals #InnovationSpotlight #RatioTherapeutics #PrecisionOncology

Check out this article from Kevin Dunleavy of Fierce Pharma describing why 2024 was a big year for radiopharma and how advancements in targeted cancer treatments are fueling billions in investments. Last year, Ratio took a major step forward with our licensing deal with Novartis, and we’re proud to be part of this exciting evolution, working on next-generation radiopharmaceuticals and driving progress in the fight against cancer. Read the full article here: https://lnkd.in/em-AV6i6 #radiopharmaceuticals #radiotherapeutics

In this Innovation Spotlight, John Babich, Co-founder, President, and Chief Scientific Officer of Ratio Therapeutics, dives into the science of radiopharmaceuticals and their transformative role in cancer care. At Ratio, we envision these targeted therapies playing a central role in personalized cancer treatment. From pre-surgery applications to enhancing immunotherapy, radiopharmaceuticals are poised to revolutionize patient care. Read the full article at The Scientist: https://lnkd.in/eQAmz6cw #CancerTreatment #Radiopharmaceuticals #InnovationSpotlight #RatioTherapeutics #PrecisionOncology

Next week, team Ratio will be in San Francisco during the 2025 J.P. Morgan Healthcare Conference. Reach out today to schedule a meeting. Learn more about our work: https://ratiotx.com #JPM25 #JPM2025

2024 has been an incredible year for us at Ratio. As we dive into 2025, let’s take a look back at some of our highlights from the past year. We look forward to continuing our mission in developing best-in-class targeted radiotherapeutics for cancer patients in the new year! #2024Wrapped